Synopsis
Synopsis
0
JDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Citrate, Norflex Orphenadrine
2. Citrate, Orphenadrine
3. Disipal
4. Hydrochloride, Orphenadrine
5. Lysantin
6. Mefenamine
7. Mefenamine, Sodium
8. Mephenamine
9. Methyldiphenylhydramine
10. Norflex
11. Norflex Orphenadrine Citrate
12. Orphenadrine
13. Orphenadrine Citrate, Norflex
14. Orphenadrine Hydrochloride
15. Sodium Mefenamine
1. 4682-36-4
2. Norflex
3. Banflex
4. Orphenadrine Dihydrogen Citrate
5. Flexon
6. Orphenadrine (citrate)
7. Flexoject
8. X-otag
9. Orphenadrine Citrate Salt
10. 2-hydroxypropane-1,2,3-tricarboxylic Acid; Dimethyl({2-[(2-methylphenyl)(phenyl)methoxy]ethyl})amine
11. 4596-23-0
12. Nsc-757238
13. Orphenadrine Citrate [usp]
14. N,n-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine;2-hydroxypropane-1,2,3-tricarboxylic Acid
15. Orphenadrine Citrate (norflex)
16. Chebi:7790
17. X0a40n8i4s
18. N,n-dimethyl-2-(phenyl(o-tolyl)methoxy)ethanamine 2-hydroxypropane-1,2,3-tricarboxylate
19. Ncgc00094745-01
20. Plenactol
21. Euflex
22. Flexor
23. Tega-flex
24. Orphenadrine Citrate (usp)
25. Dsstox_cid_24678
26. Dsstox_rid_80390
27. Dsstox_gsid_44678
28. Norflex (pharmaceutical)
29. Orphenadrinecitrate
30. N,n-dimethyl-2-(phenyl(o-tolyl)methoxy)ethan-1-amine 2-hydroxypropane-1,2,3-tricarboxylate
31. Cas-4682-36-4
32. Einecs 225-137-5
33. Unii-x0a40n8i4s
34. Norflex (tn)
35. Orphenadine Citrate
36. N,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine Citrate (1:1)
37. Ethanamine, N,n-dimethyl-2-((2-methylphenyl)phenylmethoxy)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
38. Mls000069549
39. Schembl119470
40. Spectrum1500447
41. Chembl1200395
42. Dtxsid8044678
43. Hms502k15
44. Hy-b0369a
45. Orphenadrine Citrate [mi]
46. Hms1920d10
47. Hms2091l10
48. Hms2231j06
49. Hms3259m21
50. Hms3370m12
51. Hms3651a10
52. Hms3884m22
53. Pharmakon1600-01500447
54. Citric Acid; N,n-dimethyl-2-[o-tolyl(phenyl)methoxy]ethanamine
55. O-methyldiphenhydramine Citrate Salt
56. Orphenadrine Citrate [vandf]
57. Tox21_111323
58. Tox21_113543
59. Tox21_301079
60. Ccg-40242
61. Nsc757238
62. Orphenadrine Citrate [mart.]
63. Orphenadrine Citrate [who-dd]
64. Akos008132385
65. Tox21_111323_1
66. Nc00525
67. Nsc 757238
68. (+-)-n,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine Citrate (1:1)
69. Ethylamine, N,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)-, Citrate (1:1)
70. Ncgc00015771-13
71. Ncgc00094745-02
72. Ncgc00094745-03
73. Ncgc00254980-01
74. As-74807
75. Ethanamine, N,n-dimethyl-2-((2-methylphenyl)phenylmethoxy)-, (+-)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
76. Orphenadrine Citrate [ep Impurity]
77. Orphenadrine Citrate [orange Book]
78. Smr000058817
79. Orphenadrine Citrate [ep Monograph]
80. Orphenadrine Citrate [usp Monograph]
81. Ft-0655842
82. Ft-0673305
83. S2054
84. Sw102176-4
85. En300-53019
86. Norgesic Component Orphenadrine Citrate
87. C75247
88. D00774
89. Invagesic Component Orphenadrine Citrate
90. Orphenadrine Citrate Component Of Norgesic
91. Orphengesic Component Orphenadrine Citrate
92. A826945
93. Orphenadrine Citrate Component Of Invagesic
94. Orphenadrine Citrate Component Of Orphengesic
95. Sr-01000002975-5
96. Invagesic Forte Component Orphenadrine Citrate
97. Orphengesic Forte Component Orphenadrine Citrate
98. Q27107584
99. Orphenadrine Citrate Component Of Invagesic Forte
100. Orphenadrine Citrate Component Of Orphengesic Forte
101. Beta-dimethylaminoethyl 2-methylbenzhydryl Ether Citrate Salt
102. N,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine Citrate
103. (+-)-n,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine Citrate
104. (+/-)-n,n-dimethyl-2-((o-methyl-.alpha.-phenylbenzyl)oxy)ethylamine Citrate (1:1)
105. Ethanamine, N,n-dimethyl-2-((2-methylphenyl)phenylmethoxy)-, (+/-)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
106. Ethanamine, N,n-dimethyl-2-[(2-methylphenyl)phenylmethoxy]-,2-hydroxy-1,2,3-propanetricarboxylate (1:1)
107. N,n-dimethyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine 2-hydroxypropane-1,2,3-tricarboxylate
Molecular Weight | 461.5 g/mol |
---|---|
Molecular Formula | C24H31NO8 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 11 |
Exact Mass | 461.20496695 g/mol |
Monoisotopic Mass | 461.20496695 g/mol |
Topological Polar Surface Area | 145 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 488 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Norflex |
PubMed Health | Orphenadrine |
Drug Classes | Skeletal Muscle Relaxant, Centrally Acting |
Drug Label | Orphenadrine citrate is the citrate salt of orphenadrine (2-dimethylaminoethyl 2- methylbenzhydryl ether citrate). It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly solubl... |
Active Ingredient | Orphenadrine citrate |
Dosage Form | Injectable |
Route | Injection |
Strength | 30mg/ml |
Market Status | Prescription |
Company | Medicis |
2 of 4 | |
---|---|
Drug Name | Orphenadrine citrate |
PubMed Health | Orphenadrine Citrate/Aspirin/Caffeine (By mouth) |
Drug Classes | Skeletal Muscle Relaxant, Centrally Acting/Salicylate, Aspirin Combination |
Drug Label | Orphenadrine citrate is the citrate salt of orphenadrine. It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol. The chemical name of orphenadrine citrate i... |
Active Ingredient | Orphenadrine citrate |
Dosage Form | Tablet, extended release; Injectable |
Route | Injection; Oral |
Strength | 30mg/ml; 100mg |
Market Status | Prescription |
Company | Impax Pharms; Tedor Pharma; Sandoz; Invagen Pharms; Watson Labs; Gavis Pharms; Sagent Pharms; Eurohlth Intl; Akorn |
3 of 4 | |
---|---|
Drug Name | Norflex |
PubMed Health | Orphenadrine |
Drug Classes | Skeletal Muscle Relaxant, Centrally Acting |
Drug Label | Orphenadrine citrate is the citrate salt of orphenadrine (2-dimethylaminoethyl 2- methylbenzhydryl ether citrate). It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly solubl... |
Active Ingredient | Orphenadrine citrate |
Dosage Form | Injectable |
Route | Injection |
Strength | 30mg/ml |
Market Status | Prescription |
Company | Medicis |
4 of 4 | |
---|---|
Drug Name | Orphenadrine citrate |
PubMed Health | Orphenadrine Citrate/Aspirin/Caffeine (By mouth) |
Drug Classes | Skeletal Muscle Relaxant, Centrally Acting/Salicylate, Aspirin Combination |
Drug Label | Orphenadrine citrate is the citrate salt of orphenadrine. It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol. The chemical name of orphenadrine citrate i... |
Active Ingredient | Orphenadrine citrate |
Dosage Form | Tablet, extended release; Injectable |
Route | Injection; Oral |
Strength | 30mg/ml; 100mg |
Market Status | Prescription |
Company | Impax Pharms; Tedor Pharma; Sandoz; Invagen Pharms; Watson Labs; Gavis Pharms; Sagent Pharms; Eurohlth Intl; Akorn |
Cytochrome P-450 CYP2B6 Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2B6. (See all compounds classified as Cytochrome P-450 CYP2B6 Inhibitors.)
Antiparkinson Agents
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Muscle Relaxants, Central
A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
M - Musculo-skeletal system
M03 - Muscle relaxants
M03B - Muscle relaxants, centrally acting agents
M03BC - Ethers, chemically close to antihistamines
M03BC01 - Orphenadrine (citrate)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?